ROARABLE
Today ⌘ Pro Terminal Big Ideas 🎲 Predictions Screener 🦋 Butterfly 8 Analysts 🏛️ Policy 🎬 Video ★ Watchlist 🎲 Prediction Markets 📊 RQD Track Record 📅 Next Catalysts 🛡️ Overlap & Crash X-Ray 📰 Live Wire 🐋 13F Whales 🏛️ Congress & CEO Buys 🏆 $100K Arena ⌘ Pro Terminal 📐 Methodology & Corrections
Stock Ratings / Health Care / SGP
IRMD (59) AORT (41) PRCT (40) SIBN (53) ⌘ Pro Terminal →

SpyGlass Pharma Inc. (SGP) — RQD Stock Rating Cockpit

$32.24 -0.83% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $32.13

SpyGlass Pharma Inc. (SGP) carries a Roarable Rating of D- (Sell) with 43/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (43/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →
ROARABLE D- • SELL / AVOID Cap $1.09B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on SGP Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is SGP stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-02, SpyGlass Pharma Inc. (NASDAQ: SGP) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 43/100 at a spot price of $32.24 (-0.83% 1D, market cap $1.09B). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 15/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, SGP ranks #455 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does SGP compare to IRMD and AORT in the Health Care sector?
▼

Within the Health Care sector (Medical/Dental Instruments), SGP carries a Roarable D- (43/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, IRMD (iRadimed Corporation) holds a C- grade (59/100 RQD, P/E 48.8x, ROIC 37.7%, cap $1.10B) and AORT (Artivion Inc.) posts a D- grade (41/100 RQD, P/E 117.0x, ROIC 4.5%, cap $1.14B). Among the 5-stock peer group, IRMD leads on earnings multiple (48.8x) while IRMD leads on capital efficiency (37.7% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for SGP?
▼

Per SGP's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001778922), SpyGlass Pharma Inc. generated $0 in revenue, -$39.9M in net income, and -$33.5M in free cash flow against $115.9M in total assets and $0 in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $32.13 (-0.34%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (43/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-6.7% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D-
025507510043
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D
Cash (7)Whales (15)SEC (10)Macro (8)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-6.8% Base Target
$36 Bull$30 Base$23 Bear
📬 FREE SGP RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for SGP)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (43/100 Composite)
🔍 WHY SGP SCORES 43/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+15/20 pts (35% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (23% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
35
Grade E$24.86-1% Next Q
Q2 (-2Q)
38
Grade E$24.60+21.6% Next Q
Q3 (-1Q)
40
Grade D$29.91+7.8% Next Q
Current
43
Grade D-$32.24-6.7% Hist 90D α
Trajectory: E (35) → D- (43)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a SGP Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While SGP currently carries a cautious 43/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Big institutional funds and options desks are actively positioning on the bullish side.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($27.35) and Max Pain ($33.85) forces dealer call-delta covering toward $35.53.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $SGP• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “SGP Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 43%NO 57%Trade / Inspect Odds →
RSI-14 MOMENTUMOVERBOUGHT (>70)
72.130 Oversold · 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
3.80>3.0 Fortress Safe
PIOTROSKI F-SCOREWEAK QUALITY (1–4)
2 / 99-Pt Accounting
52-WEEK LASER RANGE90% OF RANGE
L: $17$32.24H: $34
1. Money & Cash Health● WEAK
Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: D-RQD 7 / 20
2. Big Money & Insiders● TRIMMING
Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: DRQD 18 / 40
3. Hidden Risks & Market Weather● WARNING
SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: DRQD 18 / 40
MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bearish Warning on SGP

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BEARISH (35)

-35.0% ROIC with 42.0% gross margin and -3.08% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BEARISH (50)

Altman-Z 4.20 and Piotroski 2/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BEARISH (43)

18/40 institutional & smart-money positioning score with 8/20 macro alignment.

Bull Case: Why Buyers Like SGP
  • ✓Big institutional funds and options desks are actively positioning on the bullish side.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
  • !Sensitive to high interest rates and tighter Federal Reserve market liquidity.
  • !Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring SGP)

  • ✓Walkthrough of SGP's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
SGP // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +32.08%📐 HORIZONTAL RANGE
2026-11-02O $32.86H $32.86L $32.24C $32.24VOL 125.4K
RES: $33.97SUP: $21.74SMA50: $27.35SMA200: $24.41
$35.01$30.15$25.28$20.42$15.55RES $33.97SUP $21.74$32.242026-05-042026-06-172026-08-042026-09-172026-11-02
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

SGP Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 SGP Butterfly Map → + Track SGP →
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on SGP today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for SGP. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for SGP today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SGP)

Health Care Rank #455 of 1016 ⚔️ IRMD vs SGP Full Matrix →

1. Head-to-Head Health Care Peer Comparison (SGP vs. IRMD, AORT, PRCT, SIBN)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, SpyGlass Pharma Inc. (SGP) ranks #455 by composite RQD confidence (43/100, grade D-) and #354 by equity capitalization ($1.09B). Within this direct 5-issuer industry benchmark cohort, IRMD leads on earnings valuation at 48.8x trailing P/E, while IRMD leads on capital efficiency and profitability with 37.7% ROIC and 76.7% gross margin. IRMD currently holds the highest overall quantitative score in the immediate peer group at 59/100 (C-) compared with SGP at 43/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
SGP ACTIVE
SpyGlass Pharma Inc.
D- 43/100 — — -35.0% -0.83% $1.09B Benchmark Subject
IRMD
iRadimed Corporation
C- 59/100 48.8x 76.7% 37.7% -10.57% $1.10B /irmd-vs-sgp →
AORT
Artivion Inc.
D- 41/100 117.0x 64.4% 4.5% -3.67% $1.14B /aort-vs-sgp →
PRCT
PROCEPT BioRobotics Corporation
D- 40/100 — 63.7% -35.0% -5.42% $1.16B /prct-vs-sgp →
SIBN
SI-BONE Inc.
D+ 53/100 — 79.6% -10.3% -5.27% $1.00B /sibn-vs-sgp →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2024–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001778922

In its most recent audited fiscal period (FY2025, filed 2025-12-31), SpyGlass Pharma Inc. (SGP) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$39.9M, operating cash flow of -$32.7M, and free cash flow of -$33.5M (-39.4% YoY). On the balance sheet, SGP closed FY2025 with $115.9M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $0 -$39.9M -$32.7M -$33.5M $115.9M —
FY2024 (FY) 2024-12-31 $0 -$29.2M -$22.0M -$24.0M $23.3M —

3. SGP Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is SGP stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-02, SpyGlass Pharma Inc. (NASDAQ: SGP) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 43/100 at a spot price of $32.24 (-0.83% 1D, market cap $1.09B). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 15/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, SGP ranks #455 in composite RQD confidence.

How does SGP compare to IRMD and AORT in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), SGP carries a Roarable D- (43/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, IRMD (iRadimed Corporation) holds a C- grade (59/100 RQD, P/E 48.8x, ROIC 37.7%, cap $1.10B) and AORT (Artivion Inc.) posts a D- grade (41/100 RQD, P/E 117.0x, ROIC 4.5%, cap $1.14B). Among the 5-stock peer group, IRMD leads on earnings multiple (48.8x) while IRMD leads on capital efficiency (37.7% ROIC).

What are the biggest fundamental strengths and SEC risk factors for SGP?

Per SGP's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001778922), SpyGlass Pharma Inc. generated $0 in revenue, -$39.9M in net income, and -$33.5M in free cash flow against $115.9M in total assets and $0 in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is SGP trading relative to its 50-day, 200-day, and 52-week technical levels?

SGP last traded at $32.24 (-0.83% on volume of 94,152 shares), positioning the stock +17.88% above its 50-day simple moving average ($27.35) and +32.08% above its 200-day simple moving average ($24.41). Across its 52-week range of $17.06 to $33.84, SGP sits at the 90.5% percentile with a 14-day RSI of 72.1 (OVERBOUGHT (>70)) and an implied next-earnings move of ±12.5% ($28.21 to $36.27).

SGP Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell SGP stock right now?

SpyGlass Pharma Inc. (SGP) currently earns a Roarable Rating of D- (Sell — SELL) with 43/100 RQD Confidence. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

What is SGP's 12-month price target and RQD AI Jury consensus?

SGP's 12-month base price target is $30.06 (range $23.45 to $35.53), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: SGP RQD Cockpit SGP 12M Forecast SGP Earnings & Move SGP Dividends & DRIP SGP Insiders & 13F SGP Whale Options SGP Profit Sankey SGP News & Why
ROARABLE RATING BRIEF • RQD 43/100 (D-) ✓ STAGE-C NUMBER FIREWALL VERIFIED

SGP — SpyGlass Pharma Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:30:47Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, SpyGlass Pharma scores 43 out of 100 with a letter grade of D- and the verdict label "Roarable Sell — Vulnerable Balance Sheet & Flow." Across the five pillars:

  • Fundamental Cash Engine: 7 / 20. The lowest-scoring pillar is tied to a ROIC of -35% and an FCF yield of -3.08%. For a prospective investor, this means the business is currently consuming capital rather than generating it relative to the capital invested. Any valuation case must rest on future cash generation that the source data does not show yet.
  • Whale 13F Flow: 15 / 20. Institutional accumulation and options positioning score moderately well. This suggests some institutional interest, though the source data does not itemize holdings, so the strength of this signal cannot be verified here.
  • Insider Conviction: 3 / 20. SEC Form 4 and Congressional PTR cluster flow scores very weakly. The implication is that insider activity in the source data does not signal strong management conviction.
  • Macro Regime Fit: 8 / 20. With a beta of 1.0 and a sector-sensitivity read, the stock tracks broad market movement without an identified defensive offset in the source data.
  • Forensic Balance Sheet: 10 / 20. Altman Z-Score of 2.5, Piotroski F-Score of 2/9, and Debt/Equity of 0.5 together point to a balance sheet that carries meaningful financial-health questions despite moderate leverage.

Overall, the upside case depends on a turn in cash generation and on continued institutional support, while the downside case is anchored in negative ROIC, weak insider signals, and a weak Piotroski reading. Valuation tradeoffs are difficult to assess because earnings-based multiples are not available in source data.

Business

SpyGlass Pharma Inc. is a NASDAQ-listed issuer in the Health Care sector, within the Medical/Dental Instruments industry. Per the profile, the company has a market capitalization of $1.1B. The source data does not describe its products, customers, or specific revenue model. Reported revenue for FY 2025 and FY 2024 is $0.0M in each period, so the source data does not show a revenue-generating operating base in the reported periods.

Financial Trend

PeriodRevenueOperating IncomeNet IncomeEPSFCFCashDebt
FY 2025$0.0M$-41.4M$-39.9MN/A$-33.5M$96.4MN/A
FY 2024$0.0M$-27.1M$-29.2MN/A$-24.0M$16.3MN/A

Per the SEC financials, both reported periods show operating losses, net losses, and negative free cash flow. Gross, operating, and net margins are each listed at 0%. ROIC is -35%, and per the Roarable RQD rating the Altman Z-Score is 2.5 and the Piotroski F-Score is 2/9. Cash increased from $16.3M to $96.4M between the two periods, while debt is reported as N/A in both.

Recent Catalysts & News Wire Analysis

Per the recent news and catalysts feed, six items are tagged to SGP:

  • A TradingView estimates report (YELLOW, Market Wire) and a MarketBeat gap-up item (YELLOW, Market Wire) refer to short-term price action and positioning without specific detail.
  • A Simply Wall St item (YELLOW, Market Wire) refers to four-year trial data and whether the stock trades below fair value.
  • A Stock Titan item (RED, Risk Watch) reports that four years on, 18 of 21 patients remained off eye-pressure drops. This is the only item flagged as a risk watch.
  • A MarketBeat item (YELLOW, Market Wire) refers to an average price target of $44.00.
  • A second MarketBeat gap-up item (YELLOW, Market Wire) refers to a price move without further detail.

Per the Butterfly Supply-Chain Graph, there are no supply-chain links and no proprietary signals for this ticker.

Open Questions

  • What products or services generate the company's commercial activity, given zero reported revenue in both periods?
  • What is the company's debt position, since debt is reported as N/A in both periods despite a Debt/Equity ratio of 0.5?
  • What is the path to positive free cash flow and improved ROIC, and what cash runway does the $96.4M cash balance provide at the FY 2025 burn rate?
  • Who issued the $44.00 average price target, and what is the analyst coverage behind it?
  • What did the four-year trial data show in full, and how does it bear on the company's near-term financial trajectory?

SGP Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for SpyGlass Pharma Inc. (SGP) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to SGP Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

SGP Bull vs. Bear Conversation Board — What's Your Call at $32.24?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON SGP 🐻 67% BEARISH CONVICTION
1. Pick Your Side on SGP:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $28.61 (-12.0%)
📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is SGP (D- • RQD 43/100) a Buy at $32.51?

Welcome to the SGP (SpyGlass Pharma Inc.) Roar Pit. Current RQD Composite is 43/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Medical/Dental Instruments. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

SH ShortSeller_Dan Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $25.68 (-21.0%)
Spot @ $32.51

Pump the brakes on SGP — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on SGP, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless SpyGlass Pharma Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

CA CashFlowKing Verified K Arena Trader 🐂 BULLISH 🎯 Target: $40.31 (+24.0%)
Spot @ $32.51

SGP cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on SGP, the market is fixating on short-term headline noise in Medical/Dental Instruments and ignoring the balance sheet and cash flow trajectory. At $32.51 (52-wk range $17.06 - $33.84), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $755.72 -0.38% QQQ $690.49 -1.44% DIA $517.13 -0.37% IWM $279.33 +0.96% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.36 -0.94% GLD $355.78 -1.34%